Macrogenics (FRA:M55) 3-Year Share Buyback Ratio: -0.90% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:M55 Macrogenics Inc FRA:M55
50 GF Score
Price €3.44
GF Value €3.12
! 6 Warning Signs
View Full Analysis

What is Macrogenics 3-Year Share Buyback Ratio?

Macrogenics FRA:M55 +1.18% 50 3-Year Share Buyback Ratio is -0.90 as of Jun. 2026. GuruFocus rates FRA:M55 with a GF Score™ of 50/100 and a GF Value™ of €3.12. The stock has 6 warning signs investors should review. Among 1,186 Biotechnology companies, Macrogenics ranks better than 82.97% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Macrogenics's current 3-Year Share Buyback Ratio was -0.90%.

The historical rank and industry rank for Macrogenics's 3-Year Share Buyback Ratio or its related term are showing as below:

FRA:M55' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -15.1   Med: -8.8   Max: -0.8
Current: -0.9

During the past 13 years, Macrogenics's highest 3-Year Share Buyback Ratio was -0.80%. The lowest was -15.10%. And the median was -8.80%.

FRA:M55's 3-Year Share Buyback Ratio is ranked better than
82.97% of 1186 companies
in the Biotechnology industry
Industry Median: -11.6 vs FRA:M55: -0.90

Macrogenics (FRA:M55) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Macrogenics 3-Year Share Buyback Ratio Related Terms


FRA:M55 vs WHWK, SRZN, SION: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Macrogenics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Macrogenics's 3-Year Share Buyback Ratio falls into.


FRA:M55
50GF Score
Macrogenics Inc FRA:M55
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -0.90 mean?
Macrogenics (FRA:M55) has a 3-Year Share Buyback Ratio of -0.90 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Macrogenics and its competitors. According to the industry distribution chart, Macrogenics ranks #202 out of 1186 companies in the Biotechnology industry, placing it in the top 17%.
Is Macrogenics' 3-Year Share Buyback Ratio too high?
Macrogenics' current 3-Year Share Buyback Ratio is -0.90. Based on the distribution chart, Macrogenics ranks #202 out of 1186 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Macrogenics has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' 3-Year Share Buyback Ratio compare to WHWK and SRZN?
According to the Biotechnology industry distribution chart, Macrogenics ranks #202 out of 1186 companies for 3-Year Share Buyback Ratio. This places Macrogenics in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Macrogenics and its competitors. Macrogenics's current 3-Year Share Buyback Ratio is -0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Macrogenics (FRA:M55) has a current 3-Year Share Buyback Ratio of -0.90. The stock's GF Value™ is €3.12, compared to a current price of €3.44 — trading 10.3% above its estimated fair value. The current 3-Year Share Buyback Ratio is -0.90. Macrogenics' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current 3-Year Share Buyback Ratio is -0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €3.44 is trading 10.3% above its estimated GF Value™ of €3.12.

Key valuation signals for FRA:M55:

  • 3-Year Share Buyback Ratio: -0.90
  • GF Value™: €3.12 vs. price of €3.44 (10.3% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
50GF Score

Get the complete analysis for FRA:M55

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.44
Price
€3.12
GF Value